2.29
+0.065(+2.93%)
Currency In USD
| Previous Close | 2.22 |
| Open | 2.19 |
| Day High | 2.33 |
| Day Low | 2.17 |
| 52-Week High | 6.89 |
| 52-Week Low | 0.56 |
| Volume | 463,467 |
| Average Volume | 5.87M |
| Market Cap | 36.08M |
| PE | -2.28 |
| EPS | -1 |
| Moving Average 50 Days | 2.1 |
| Moving Average 200 Days | 1.2 |
| Change | 0.07 |
If you invested $1000 in iBio, Inc. (IBIO) 10 years ago, it would be worth $0.82 as of February 17, 2026 at a share price of $2.285. Whereas If you bought $1000 worth of iBio, Inc. (IBIO) shares 5 years ago, it would be worth $2.23 as of February 17, 2026 at a share price of $2.285.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
iBio Announces $26 Million Private Placement
GlobeNewswire Inc.
Jan 09, 2026 12:00 PM GMT
SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it has entered into a securities purchase agreement with existing healthcare-focused, high-quality i
iBio to Participate in the 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 24, 2025 9:15 PM GMT
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the 8th Annual Evercore Healthcare Conference, taking place December 2–4, 20
iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance
GlobeNewswire Inc.
Oct 30, 2025 11:00 AM GMT
Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment discontinuation New non-human primate data projects a human